1. Home
  2. DELL vs NVO Comparison

DELL vs NVO Comparison

Compare DELL & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DELL

Dell Technologies Inc.

HOLD

Current Price

$395.57

Market Cap

191.7B

Sector

Technology

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$43.88

Market Cap

197.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DELL
NVO
Founded
1984
1923
Country
United States
Denmark
Employees
N/A
69500
Industry
Computer Manufacturing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
191.7B
197.4B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
DELL
NVO
Price
$395.57
$43.88
Analyst Decision
Buy
Hold
Analyst Count
17
11
Target Price
$181.63
$51.00
AVG Volume (30 Days)
9.6M
11.3M
Earning Date
05-28-2026
05-06-2026
Dividend Yield
1.23%
3.19%
EPS Growth
36.05
N/A
EPS
5.24
N/A
Revenue
$113,538,000,000.00
N/A
Revenue This Year
$26.19
N/A
Revenue Next Year
$8.60
$3.70
P/E Ratio
$74.75
$13.60
Revenue Growth
18.80
N/A
52 Week Low
$110.22
$35.12
52 Week High
$469.47
$71.80

Technical Indicators

Market Signals
Indicator
DELL
NVO
Relative Strength Index (RSI) 64.92 52.92
Support Level $126.13 $43.35
Resistance Level $469.47 $46.05
Average True Range (ATR) 27.72 1.37
MACD -2.74 -0.18
Stochastic Oscillator 57.91 61.34

Price Performance

Historical Comparison
DELL
NVO

About DELL Dell Technologies Inc.

Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners and also relies heavily on channel partners to fulfill its sales.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: